In this article, we will discuss: 5 Best Day Trading Stocks to Buy Now. For more stocks, you can head to 11 Best Day Trading Stocks to Buy Now.
5. Hims & Hers Health, Inc. (NYSE:HIMS)
Number of Hedge Fund Holdings: 39
Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock. Barclays commented that the fact that Hims & Hers Health, Inc. (NYSE:HIMS)’s shares had performed well after its agreement with Novo Nordisk indicated that the firm’s legal woes were behind it. Barclays added that the market appeared to be underestimating the opportunities for new products from new products.
Barclays coverage came after Novo Nordisk announced that it had decided to drop its legal action against Hims & Hers Health, Inc. (NYSE:HIMS) for what the healthcare company dubbed an illegal compound dispute. Novo had taken the action after Hims & Hers Health, Inc. (NYSE:HIMS) had announced that it would sell its own weight loss pill. The development came after the pair had ended their partnership last year to provide discounted weight loss shots to Hims & Hers Health, Inc. (NYSE:HIMS)’s customers.
Hims & Hers Health, Inc. (NYSE:HIMS) is a health platform that offers prescription and non-prescription products to consumers. The firm is headquartered in San Francisco, California.
4. Figure Technology Solutions, Inc. (NASDAQ:FIGR)
Number of Hedge Fund Holdings: 40
Financial firm Mizuho discussed technology company Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s shares on March 10th. It lowered the share price target to $55 from $64 and kept an Outperform rating on the stock. As part of its coverage, the financial firm outlined that it continued to be optimistic about Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s long term growth potential. The technology firm partnered up with BitGo Holdings in February to complete the world’s first fully on-chain equity trades through which shares were issued, traded, and settled through blockchain technology.
Investment firm Piper Sandler discussed Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s shares in January. It raised the price target to $75 from $55 and kept an Overweight rating on the stock. The coverage came after the technology company reported its earnings for the fourth quarter of 2025. The results saw Figure Technology Solutions, Inc. (NASDAQ:FIGR)’s total client loans jump to $2.7 billion from $1.17 billion from the year-ago quarter.
Figure Technology Solutions, Inc. (NASDAQ:FIGR) is a technology company that provides a blockchain-based market platform for trading and investing. It is headquartered in Reno, Nevada.
3. Dyne Therapeutics Inc. (NASDAQ:DYN)
Number of Hedge Fund Holdings: 61
Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs. The firm revealed that it planned to submit an accelerated application for its DMD drug to target a launch in the first quarter of 2027. Dyne Therapeutics Inc. (NASDAQ:DYN) added that for DM1, it had completed enrollment for a Phase 1/2 trial. On March 8th, the firm revealed that it had started a Phase 3 trial of the drug DYNE-101 for the disease, and on the same day, Dyne Therapeutics Inc. (NASDAQ:DYN) revealed that its Phase 1/2 DELIVER trial for DMD had shown results when it came to baseline in lung function and other metrics.
Investment bank Morgan Stanley discussed the pharmaceutical company’s shares on March 3rd. It reduced the share price target to $47 from $50 and kept an Overweight rating, according to The Fly. Morgan Stanley outlined that Dyne Therapeutics Inc. (NASDAQ:DYN)’s programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) were on track, and 2026 could see the firm execute on its key programs.
Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company focusing on developing treatments for neuromuscular diseases. It is headquartered in Waltham, Massachusetts.
2. Mineralys Therapeutics Inc. (NASDAQ:MLYS)
Number of Hedge Fund Holdings: 88
Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for its lorundrostat drug to treat hypertension when combined with other hypertensive drugs. As part of the release, the firm’s CEO outlined that while the drug’s Explore-OSA trial did not show a reduction in the apnea-hypopnea index (AHI), the drug’s safety profile and its impact on blood pressure were nevertheless meaningful.
The FDA’s NDA approval came after Mineralys Therapeutics Inc. (NASDAQ:MLYS) announced in January that it had submitted the application. In December 2025, Bank of America raised the firm’s share price target to $46 from $43 and kept a Buy rating on the stock. The coverage came after Mineralys Therapeutics Inc. (NASDAQ:MLYS)’s earnings report for the third quarter of 2025, which saw the firm confirm that it had a cash runway up to 2027.
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a biotechnology company that is focused on developing drugs for ailments stemming from aldosterone dysregulation. It is headquartered in Radnor, Pennsylvania.
1. Lumentum Holdings Inc. (NASDAQ:LITE)
Number of Hedge Fund Holdings: 97
Investment bank Barclays discussed photonics and optical products manufacturer Lumentum Holdings Inc. (NASDAQ:LITE)’s shares on March 3rd. It raised the share price target to $750 from $475 and kept an Equal-Weight rating on the shares. The coverage came a month after Lumentum Holdings Inc. (NASDAQ:LITE) reported its earnings for the second fiscal quarter of 2026. The results saw the firm report $665 million in revenue and $143 million in non-GAAP net income.
On the same day, Rosenblatt also discussed Lumentum Holdings Inc. (NASDAQ:LITE)’s shares. It raised the share price target to $900 from $580 and kept a Buy rating on the stock. Rosenblatt pointed out that the firm will benefit from AI chip giant NVIDIA’s decision to invest $2 billion in it and to secure future capacity for optical products. Like the two financial firms, investment bank Morgan Stanley is also optimistic about Lumentum Holdings Inc. (NASDAQ:LITE). It raised the price target to $520 from $420 and kept an Equal Weight rating on the shares.
Lumentum Holdings Inc. (NASDAQ:LITE) is an American company that makes and sells optical and photonic products used in computing and other applications. It is headquartered in San Jose, California.
While we acknowledge the potential of LITE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LITE and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
